Cadila Healthcare is currently trading at Rs. 421.65, up by 10.60 points or 2.58% from its previous closing of Rs. 411.05 on the BSE.
The scrip opened at Rs. 424.95 and has touched a high and low of Rs. 433.05 and Rs. 421.65 respectively. So far 26,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 356.30 on 16-Feb-2017.
Last one week high and low of the scrip stood at Rs. 433.05 and Rs. 373.05 respectively. The current market cap of the company is Rs. 43,294.00 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.93% and 8.28% respectively.
Cadila Healthcare has successfully completed the US Food and Drug Administration (USFDA) inspection at its Moraiya facility. USFDA had inspected the Moraiya facility from February 5 to February 9, 2018. At the end of the inspection, no observation (483) is issued.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
